Degron Therapeutics
- Biotech or pharma, therapeutic R&D
Degron Therapeutics is developing a new class of small molecule molecular glue degrader (MGD) drugs using GlueXplorer®, a proprietary molecular glue-based targeted protein degradation drug discovery platform. Degron has built an unique MGD library based on novel scaffold chemistry that enables new targets discovery. In May 2024, we entered into a $1.2B collaboration and license agreement with Takeda to develop novel MGDs for multiple targets in oncology, neuroscience, and inflammation.
Leveraging our platform, we have developed a robust pipeline of novel MGD programs in oncology and inflammation/immunology. Our most advanced program, a first-in-class MGD for the RNA binding protein, HuR, has received FDA clearance to initiate clinical development in solid tumors and we expect to have FPI by Q3 2025. We also have multiple preclinical stage programs where we've identified and validated MGDs and are advancing into PCCs this year.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}